Renaissance Capital logo

Belite Bio Priced, Nasdaq: BLTE

Phase 2/3 biotech developing an oral therapy for retinal degeneration diseases.

Industry: Health Care

Latest Trade: $39.93 0.00 (0.0%)

First Day Return: +76.5%

Return from IPO: +565.5%

Industry: Health Care

We are a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration (commonly known as dry AMD) and autosomal recessive Stargardt disease, or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
more less
IPO Data
IPO File Date 04/05/2022
Offer Price $6.00
Price Range $5.50 - $6.50
Offer Shares (mm) 6.0
Deal Size ($mm) $36
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 04/29/2022
Offer Price $6.00
Price Range $5.50 - $6.50
Offer Shares (mm) 6.0
Deal Size ($mm) $36
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
The Benchmark Company
Company Data
Headquarters San Diego, CA, United States
Founded 2016
Employees 12
Website belitebio.com

Belite Bio (BLTE) Performance